Contraindications to Starting Tirzepatide
Tirzepatide is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). 1, 2
Absolute Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- History of serious hypersensitivity reaction to tirzepatide 3
These contraindications stem from the fact that thyroid C cells express GLP-1 receptors, and while medullary thyroid carcinoma has not been proven to be caused by GLP-1 receptor agonists in humans, the theoretical risk based on animal data warrants absolute avoidance in these populations 1, 2.
Critical Clinical Situations Requiring Extreme Caution or Avoidance
Pregnancy and Preconception
Tirzepatide must be discontinued before pregnancy. 4 The guideline evidence recommends discontinuation before conception rather than waiting until pregnancy is confirmed, as:
- Animal studies showed early pregnancy losses and fetal abnormalities with marked maternal weight loss during organogenesis
- Discontinuation causes rebound weight gain and potential hyperglycemia, both of which increase teratogenic risk if occurring during first trimester
- Manufacturers recommend stopping semaglutide 2 months before planned pregnancy; similar precautions apply to tirzepatide
Severe Renal Impairment
While not an absolute contraindication for tirzepatide specifically (unlike exenatide and lixisenatide which are contraindicated with eGFR <30), use extreme caution and close monitoring 3. Recent case reports demonstrate tirzepatide can cause:
- Acute kidney injury through direct vasodilation, natriuresis, and volume depletion 5
- Patients with end-stage renal disease have significantly increased risk (OR 2.94) of thyroid disease development during treatment 6
History of Pancreatitis
Consider alternative therapies in patients with prior pancreatitis. 1 While the evidence is conflicting and tirzepatide has been described as "safe for pancreatitis" in some guidelines 2, the prescribing information states these agents have not been adequately studied in this population. The conservative approach prioritizes patient safety given the rare but serious association.
Important Clinical Warnings and High-Risk Situations
Gallbladder and Biliary Disease
Tirzepatide increases risk of gallbladder or biliary disease 2. While not a contraindication, patients with active gallbladder disease or high risk for complications should be carefully evaluated before initiation.
Heart Failure on Guideline-Directed Medical Therapy
Patients on maximal heart failure medications require careful monitoring and likely dose adjustments 5. Case series demonstrate that tirzepatide's vasodilation, natriuresis, and volume reduction effects can cause:
- Symptomatic hypotension
- Acute kidney injury
- Need for significant modification of GDMT regimens (angiotensin receptor neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists)
Close monitoring of vital signs and volume status is mandatory after initiation, with proactive adjustment of heart failure medications.
Pre-existing Thyroid Disease
Baseline thyroid disease significantly increases risk (OR 3.78) of new or worsening thyroid disorders 6. While not a contraindication, these patients warrant:
- Periodic thyroid function testing during treatment
- Heightened surveillance for thyroid nodules or goiter development
- Consideration of alternative therapies if multiple risk factors present
Common Pitfalls to Avoid
Do not screen for medullary thyroid carcinoma with calcitonin levels - The FDA explicitly states this is not necessary 1
Do not continue tirzepatide if severe abdominal pain develops - Stop immediately and evaluate for pancreatitis 2
Do not overlook medication interactions - Tirzepatide can significantly impact blood pressure and volume status, requiring adjustment of antihypertensives and diuretics 5
Do not restart at full dose after interruption - Patients who discontinue must restart at the lowest dose and retitrate to prevent severe gastrointestinal side effects 7